June 27 (Reuters) - Innate Immunotherapeutics Ltd IIL.AX
* Results for trial of MIS416 in patients with secondary progressive multiple sclerosis show no clinically meaningful or statistically significant differences Source text for Eikon: ID:nASXc3FHb3 Further company coverage: IIL.AX